<DOC>
	<DOCNO>NCT01357720</DOCNO>
	<brief_summary>This study show vaccination 1 dose Tritanrix HB+Hib follow Quinvaxem vaccine 2nd 3rd dose inferior vaccination Quinvaxem 3 dos , respect protection antibody ( anti-hepatitis B surface antibody , anti-polyribosyl ribitol phosphate ( PRP ) , anti-diphtheria , anti-tetanus anti-Bordetella pertussis ) 1 month completion 6-10-14 week vaccination course .</brief_summary>
	<brief_title>Study Assess Quinvaxem Can Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Diphtheria Antitoxin</mesh_term>
	<criteria>A male female , include , 42 64 day age time first vaccination Written inform consent obtain parents/legal guardian subject Free obvious health problem establish medical history and/or clinical examination enter study Hepatitis B vaccination birth ( within 48 hour ) Available schedule study visit Use investigational drug investigational vaccine within 30 day precede first dose study vaccine , plan use study period safety followup Planned administration vaccine foreseen study protocol Known suspect impairment immune function , know Human immunodeficiency virus ( HIV ) positivity , receive immunosuppressive therapy , receive systemic immunosuppressive therapy within 1 month prior study entry ( note : inhaled topical steroid allow ) Administration parenteral immunoglobulin preparation and/or blood product since birth Previous vaccination Haemophilus influenzae type b ( Hib ) and/or diphtheria , tetanus , pertussis ( DTP ) History anaphylaxis , serious vaccine reaction , allergy vaccine component product contain mercury compound , sodium ethylmercurothiosalicylate Significant acute infection Any condition , opinion investigator , might interfere evaluation study objectives Participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>64 Days</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Vaccination</keyword>
	<keyword>Immunisation</keyword>
	<keyword>Virus</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Haemophilus Influenzae</keyword>
	<keyword>Immunity</keyword>
</DOC>